Table 4. Comparison of NF1 and control breast cancers by grade, pT class, lymph node and receptor statuses and the proliferative index Ki-67.
| NF1 group, n (%)a | Control group, n (%)a | OR (95% CI)b | P-value | |
|---|---|---|---|---|
| Total | 26 | 130 | ||
| Tumour grade | ||||
| I | 1 (3.8%) | 21 (18.4%) | 2.37 (1.00–5.61) | P=0.050 |
| II | 11 (42.3%) | 49 (43.0%) | ||
| III | 14 (53.8%) | 44 (38.6%) | ||
| Unknown | 0 | 16 | ||
| pT class | ||||
| 1 | 11 (42.3%) | 78 (66.1%) | 2.87 (1.19–6.90) | P=0.019 |
| 2 | 13 (50.0%) | 34 (28.8%) | ||
| 3 | 1 (3.8%) | 6 (5.1%) | ||
| 4 | 1 (3.8%) | 0 (0.0%) | ||
| Unknown | 0 | 12 | ||
| Lymph node status | ||||
| N0 | 11 (44.0%) | 53 (55.2%) | 1.53 (0.65–3.61) | P=0.332 |
| N1 | 10 (40.0%) | 30 (31.3%) | ||
| N2 | 3 (12.0%) | 10 (10.4%) | ||
| N3 | 1 (4.0%) | 3 (3.1%) | ||
| Unknown | 1 | 34 | ||
| Oestrogen receptor status | ||||
| Positive (10–100%) | 12 (46.2%) | 91 (79.1%) | 0.21 (0.07–0.53) | P=0.001 |
| Negative (0–10%) | 14 (53.8%) | 24 (20.9%) | ||
| Unknown | 0 | 15 | ||
| Progesterone receptor status | ||||
| Positive (10–100%) | 9 (34.6%) | 90 (78.3%) | 0.10 (0.03–0.29) | P<0.001 |
| Negative (0–10%) | 17 (65.4%) | 25 (21.7%) | ||
| Unknown | 0 | 15 | ||
| HER2 amplification | ||||
| Yes | 8 (30.8%) | 11 (9.6%) | 5.46 (1.67–20.11) | P=0.006 |
| No | 18 (69.2%) | 104 (90.4%) | ||
| Unknown | 0 | 15 | ||
| Triple-negative | ||||
| Yes | 5 (19.2%) | 15 (13.0%) | 1.65 (0.48–5.09) | P=0.399 |
| No | 21 (80.8%) | 100 (87.0%) | ||
| Unknown | 0 | 15 | ||
| Ki-67 status | ||||
| Mean (s.d.) | 33.3% (22.8) | 29.3% (22.5) | P=0.334 | |
| Unknown | 0 | 15 |
Abbreviations: CI=confidence interval; HER2=human epidermal growth factor receptor 2; NF1=neurofibromatosis 1; OR=odds ratio.
a
Percentage calculated for cases with known status only.
b
Odds ratios and 95% CIs are derived from generalised mixed effects models with NF1 diagnosis as the exposure variable, and a grouping variable that indexes matched sets as a random effect. Therefore, ORs illustrate the odds of NF1 patients compared with controls for each outcome.